• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Intellia Therapeutics opens new headquarters

Intellia Therapeutics opens new headquarters

December 5, 2016
CenterWatch Staff

Intellia Therapeutics, a genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, has announced the move to its new laboratory facilities at 40 Erie Street, in Cambridge.

“The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials,” said Nessan Bermingham, Ph.D., chief executive officer and founder, Intellia Therapeutics. “To reach our goals, we continue to recruit top talent and ensure our quality workforce has the appropriate facilities and tools necessary to translate CRISPR/Cas9 into life-transforming products.”

“This new facility allows Intellia to further advance our scientific programs and to continue to leverage our Massachusetts location alongside leading biotech research and academic institutions,” Dr. Bermingham added.

The new Intellia headquarters was specifically designed to accommodate the company’s growing R&D, operations teams and administrative staff. Additionally, Intellia will maintain operations at its current facility at 130 Brookline Street in Cambridge. The new facility will increase Intellia’s total laboratory and office space from the current 15,000 sq. ft. to more than 80,000 sq. ft. and will allow the company to double its team to more than 200 employees.

“Intellia Therapeutics’ new headquarters is a testament to the potential of the company and the promise their transformative gene therapy represents to patients and their families living with severe and life-threatening diseases,” said Governor Charlie Baker. “The innovations coming out of Massachusetts have a dramatic impact across the global life sciences sector, and we look forward to Intellia Therapeutics’ continued growth and contributions to this field.”

“We are thrilled to celebrate Intellia Therapeutics’ growth as a great example of the opportunity available to companies in the Massachusetts life sciences ecosystem,” said Travis McCready, president and CEO of the Massachusetts Life Sciences Center. “The genomics space is exciting, carrying enormous potential for saving lives and improving patient care. Companies like Intellia have provided a strong blueprint for success to other genomics startups in Massachusetts.”

“We are excited to celebrate with Intellia Therapeutics as they take this significant step to expand into new headquarters,” said Robert K. Coughlin, president and CEO of MassBio. “We are proud to have Intellia as part of the Massachusetts life sciences community and look forward to their successes as they advance the use of cutting-edge genome editing to develop treatments and cures for patients around the world.”

Upcoming Events

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing